Trial Profile

A Phase 1, Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ecnoglutide Tablet in Healthy Adult Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ecnoglutide (Primary)
Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Sciwind Biosciences

06 Sep 2024 According to a Sciwind Biosciences media release, data from the study will be presented at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting, to be held in Madrid, Spain, September 9 -13, 2024.
28 Jun 2024 Planned number of patients changed from 56 to 90.
28 Jun 2024 Planned End Date changed from 1 Feb 2023 to 1 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com